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1. Introduction 
Mechanical Circulation Assist Devices are designed for the treatment of acute and chronic 
heart failure and can be applied for different indications and assist period. Treatments 
that are carried out with Ventricular Assist Device System (VADs) have improved over 
course of time, within the practical applications of pediatric cardiac surgery. Pulsatile 
devices being in the lead, paracorporeal assist devices and implantable ventricular assist 
devices all have fields of application. However, ECMO (Extracorporeal Membrane 
Oxygenator) treatment is still applied on infants and children. These systems are preferred 
to assist patients with respiratory failure after heart surgery. But, this assist remains for a 
short term and compulsorily puts the patients into intensive care. In recent years, so many 
new devices have been developed, such as easily intubated cannulas for children including 
infants and miniature pumps for pediatric use. These devices are recommended for mid and 
long term, which is more predominant than ECMO. They are applied successfully to assist 
bridge to recovery and bridge to transplantation. Here, an assessment is made for different 
types of contemporary devices, decision making and application strategy, device 
technology, implantation techniques, anticoagulation and follow-up, new generation assist 
devices that operate with pediatric ventricular assist device for the treatment of pediatric 
heart failure. Proverbially, in spite of the successful results, ECMO and centrifugal pumps 
are not suitable for every patient because of the reasons such as long period of stays in 
intensive care unit, lack of mobilization and shortness of operating time. VAD systems are 
developed for little children of previously which only ECMO was suitable for. With the 
VAD treatment of selected pediatric population, especially in the cases of myocarditis and 
cardiomyopathy, mobilization and low anticoagulation have been enabled and resulted in 
90 % of survival rate. VAD is preferred instead of ECMO and if there is a need for 
circulation assist that exceeds 1-2 weeks, the complication rate decreases. These devices get 
more reliable day by day and they will play an effective role in future as a treatment method 
for the complex congenital heart diseases that aim for transplantation or bridging treatment 
for cardiac recuperation. Eventually, what is dreamt for future is to attain permanent 
solutions. 
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2. History of mechanical support device in pediatrics 
In 1974 Bartlett reported the use of extracorporeal membrane oxygenation in pediatric 
patients with respiratory failure or after repair of congenital heart disease. Bartlett first used 
the ECMO device on a neonate and named it “Esperanza”, meaning “Hope” (Bartlett et al., 
1977). In 1980 Pollock reported the first use of an intraaortic balloon pump in children 
(Pollock et al., 1980). In 1983, Veasy reported the use of small balloon catheters in 15 children 
(Veasy et al., 1983). The Thoratec ventricular assist devices have been available since the 
early 1980s, and can be implanted in children and adolescents (Reinhartz et al, 2001). The 
first neonatal oxygenator was released in the 1990s (Duncan, 2001). 
In spite of the success of ventricular assist devices for adults, not much has been done to 
develop similar devices for pediatric population. Afterwards, in 1992, the “Berlin Heart” 
offered the first commercially available system with miniaturized paracorporeal pumps and 
cannulae. The first implantation of a Medos ventricular assist device as a bridging to 
transplantation took place in 1994 (Konertz, 2001). The DeBakey VAD Child (MicroMed 
Technology, Inc. Houston, TX) became available for use in 2004 (Morales et al., 2005). 
In 1989, it was reported by ELSO (Extracorporeal Life Support Organization) that the 
number of centers that use ECMO was 100 worldwide. Until 2005, more than 30.000 
patients, with the support of ECMO, have survived with 65 % success rate (ECLS Registry, 
2005). ECLS registry in 2008 provides a database of 37.000 patients from all around the 
world with details about demographic factors, diagnosis, treatment and complications 
(Haines et al., 2009). There have been studies with 80 % success for the usage of ECMO on 
infants with acute hypoxemic respiratory failure (Field et al., 1996). On infants that undergo 
traditional treatments, the survival rate is 30 %. With ECMO support, this rate is doubled 
(Bennett et al., 2001). Currently, the support devices are applied on infants and children 
with uncontrollable heart failure. Final ECLS, ECMO guideline has been published in April 
2009. In this chapter, we will be discussing ECMO as a cardiac support device and as well as 
other mechanical cardiac support devices applied on child patients.  
3. The selection of mechanical support devices 
The selection of suitable mechanical support device is determined according to the surface 
area of the body. Mechanical support indication depends on the predetermining the length 
of time between bridging treatment and transplantation, effect of the disease, 
pathophysiological events and the fact that many organizations can obtain different devices. 
Although there have been a variety of cardiac support systems for adult patients, the 
devices for neonates and infants are scarce. Today, two of the the most common methods for 
the short term cardiac support for infants are ECMO and Centrifugal Extracorporeal VAD 
(Ventricular Assist Device) (Table 1). Nowadays, the presence of new paracorporeal VAD is 
encouraging. The technical specifications of mechanical cardiac devices used for children are 
summarized in Table 2. These systems are used in bridging treatment that extends the 
transplantation period a few months. Since the case is completed, intra-aortic balloon pump 
(IABP) will be discussed, although it is rare for pediatric patients. 
3.1 Extracorporeal membrane oxygenation (ECMO) 
ECMO is the most important assist system for mechanical heart support for pediatric 
population. There are two major methods: veno-venous ECMO, which provides ventilator 
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 ECMO VAD 
Oxygenator Yes  No 
Circulation Long, with reservoir Short, no reservoir 
Anticoagulation ACT 180-220 seconds ACT 140-160 seconds 
Air emboli Low  High (L-VDC) 
Support type Cardiorespiratory Cardiac 
Ventricular decompression Atrial septestomy/LA vent Not required 
Length of Support A few weeks Weeks 
Cannulation Transthoracic or jugular Transthoracic 
Table 1. Comparison of ECMO and centrifugal extracorporeal VAD 
 
Device 
type 
Intra-
aortic 
baloon 
pump 
ECMO Centri-
fugal 
pump 
Berlin 
Heart 
Excor 
Medos 
HIA VAD
Thoratec
II 
HeartMate 
IP/VE 
Abiomed 
BVS 5000 
Position Intraaortic External External External External External External External 
Ventri-
cular 
support 
Left Double Left, 
right or 
double 
Left,  
right or 
double 
Left,  
right or 
double 
Left,  
right or 
double 
Left Left,  
right or 
double 
Duration Short Short Short Long Short Medium 
Long 
Long Medium 
Flow Pulsatile Non -
pulsatile 
Non - 
pulsatile
Pulsatile Pulsatile Pulsatile Pulsatile Pulsatile 
Power 
Supply 
Pneumatic Electrical Electrical Pneumatic Pneumatic Pneumatic Electrical 
or 
Pneumatic 
Pneumatic 
Cannu-
lation 
Peripheric 
Artery 
Peripheric 
Artery 
and Ven 
Central 
or Peri-
pheric 
Central Central Central or 
Peripheric
Central Central 
Anticoa-
gulation 
Not 
required 
Required Not 
required 
or low 
Required Required Required Not 
required 
Required 
Mobili-
zation 
No No No Yes No Yes, 
limited 
No No 
Discharge 
from 
hospital 
No No No No No Yes Yes No 
Table 2. Technical specification of mechanical cardiac assist devices for pediatric patients 
support and the other one is veno-arterial ECMO, which is suitable for patients with 
circulatory failure and it provides both heart and lung support. ECMO is more 
advantageous than other devices in terms of its usage for patients with bi-ventricular failure, 
respiratory insufficiency and pulmonary hypertension. Discharge survival rate of a short 
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term ECMO treated patient is 40-80% (Bartlett et al., 1977). If the recovery time is prolonged, 
risk of infection increases. Since there is a complication incidence, the usage of ECMO is 
limited within a few feeks (max. 4-6 weeks) (Cahturvedi et al., 2004). For the patients that 
require a longer assistance, other types of ventricular assist devices may be suitable.  
Reports of a center’s experience usually find that conditions of complex heart disease with 
either excess pulmonary blood flow or decreased pulmonary blood flow constitute the 
majority of cases requiring ECMO for pediatric cardiac support (Duncan et al., 1999). The 
most common scenarios for support usually occur in children after cardiac surgery, namely, 
failure to wean from cardiopulmonary bypass and cardiogenic shock or cardiac arrest 
occurring in the intensive care unit postoperatively (Delius et al., 1992; Hunkeler et al., 1992; 
Raithel et al., 1992). However, nonresponsive medical conditions also occur in children that 
require mechanical circulatory support (Duncan et al., 2001; Del Nido et al., 1994). 
Conditions that represent contraindications for ECMO are now often successfully 
supported. For instance, patients with shunted single ventricle physiology, were often 
denied ECMO in the past due to difficulties in achieving balance between the pulmonary 
and systemic circulations. Due to improvements, ECMO and VADs are currently necessary 
adjuncts for the successful surgical approach to these patients (Darling et al., 2001; Pizarro et 
al., 2001). 
Since its launch, ECMO has been the predominant form of support for children. Due to the 
presence of an oxygenator in the circuit, ECMO is most useful in providing support when 
heart disease is accompanied by hypoxia and pulmonary hypertension. The presence of an 
oxygenator and other complexities of the ECMO circuit require higher levels of 
anticoagulation (Hetzer et al., 1998). 
Another important difference between devices is the impact on recovery of ventricular 
function during support. Experimental studies have shown increased ventricular wall stress 
during ECMO support while VADs provide better ventricular unloading leading to 
decreased wall stress (Ratcliffe et al., 1991). ECMO may also contribute to ongoing 
myocardial damage during support by providing desaturated blood flow to the coronary 
arteries (Kato et al., 1996). ECMO provides only short-term support, requires intensive 
nursing management, and is not suitable for ambulatory support. ECMO support is limited 
to a few weeks; after this time period, multi-system organ failure ensues, probably due to 
chronic activation of the inflammation that occurs during ECMO support. 
3.2 Centrifugal pump VAD 
Centrifugal pump systems, such as the Bio-Pump (Medtronic Bio-Medicus, Minneapolis, 
MN), are the most commonly used form of VAD support for children. Such VADs provide 
non-pulsatile flow. The centrifugal VAD circuit employs short tubing lengths to connect the 
pump to the venous and aortic cannulas, which reduces priming volumes compared to 
ECMO and makes the system easy to maintain(Karl & Horton, 2001). Heparin requirements 
as well as trauma to blood elements may be decreased with Bio-Pump-based VAD circuits 
owing to the absence of an oxygenator or venous reservoir. Despite its simplicity and 
proven track record, the main limitation for the Bio-Pump VAD, like ECMO, is its 
unsuitability for prolonged support. Thus reported excellent results using the Bio-Pump to 
support infants and children weighing 6 kg or less (Thuys et al., 1998). Utilizing this system, 
the authors supported 34 children with median age of 2 months (range 0–8 months) and 
weight of 3.7 kg (range 1.9–5.98 kg). Of 34 supported, 63 % were successfully separated from 
VAD support and 31 % of this difficult patient population survived to hospital discharge. 
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Other reports have described the utility of centrifugal VAD to support the entire spectrum 
of pediatric cardiac disease (Langley et al., 1998). 
3.3 Ventricular assist devices (VADs) 
Nonpulsatile centrifugal VADs are used for effective assistance, after a congenital heart 
surgery of neonates and infants that develop ventricular incompetence. They can be applied 
especially on patients who will undergo heart transplantation following anomalous origin of 
the left coronary artery from the pulmonary artery repair or late arterial switch operation 
and secondary pulmonary hypertension in right heart failure (Del Nido et al., 1999). 
Discharge survival rate in two studies supported by peroperative centrifugal VAD is around 
40 % and have similarities with the usage of ECMO (Duncan et al., 1999; Thuys et al., 1998). 
The biggest advantage of centrifugal VAD usage is simplicity of this circulation device. It 
provides better ventricular decompression than ECMO and does not require oxygenation 
and requires very low anticoagulation. Although, the usage of biventricular devices on 
neonates and infants is not realistic, the number of devices is only a few and it requires four 
cannulas and two pumps. The usage of univentricular VAD is not suitable for patients with 
resistant respiratory failure, pulmonary hypertension and large intracardiac shunt. It may be 
used for a few weeks for short term support. The main characteristics of ECMO with 
centrifugal VAD system are shown on Table 1. There are various devices with long term 
mechanical support, such as, from paracorporeal VADs to impeller pumps. One of the two 
paracorporeal VADs, commonly used for neonates and infants is Excor pediatric from Berlin 
Heart AG and the other is Medos HIA. These are pneumatic devices that work with 
pulsatile flow. These pumps have different types that can operate on stroke volume under 
10 ml for neonates (Merkle et al., 2003; Reinhartz et al., 2002). Thoratec paracorporeal assist 
devices can be used successfully for adult patients and child patients over 10 years of age, as 
well (Reinhartz et al., 2001). 
Paracorporeal assist devices have been applied on patients with cardiomyopathy or 
myocarditis for bridging to transplantation. Some patients have been assisted over 100 days, 
by being extubated and mobilized in the hospital. The usage of these devices for 
postcardiotomy syndrome is limited and the results are poor. There is a risk of hemorrhagic 
and thromboembolic stroke in VADs and various neurologic problems may occur (Merkle et 
al., 2003; Reinhartz et al., 2001). 
There are some advanced devices with long term mechanical support in many centers such 
as DeBakey from Micromed, Jarvik and Incor from Berlin Heart AG that have been 
produced under the description, impeller axial flow pumps (Song et al., 2003). Today, 
pediatric version of the DeBakey pump is used and it is still too early to speculate on the 
success of this pump in pediatric population. Though they have an effective use, only some 
certain pediatric VADs are approved by FDA (Table 3). 
In the United States, several FDA-approved options are available for bridging the patient to 
recovery and transplantation. These options include the following: 
1. Abiomed BVS 5000 circulatory support system (Abiomed, Inc, Danvers, Mass), which is 
typically used for short-term support 
2. Abiomed AB5000 circulatory support system (Abiomed, Inc) 
3. Centrimag or Levitronix system (Thoratec, Pleasanton, Calif) 
4. Thoratec paracorporeal and intracorporeal LVAD and RVAD (Thoratec) 
5. Novacor LVAD (World Heart Inc, Oakland, Calif) 
6. HeartMate I LVAD (Thoratec) 
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Device 
 
Brand Weight of patient Pump type 
Heart mate LVAD Thoratec  BSA> 0,7 m2 Pusher Plate 
Thoratec VAD Thoratec BSA> 0,7 m2 Pusher Plate 
Abiomed BVS 5000 Abiomed  BSA> 0,7 m2 Axial 
DeBakey VAD  Micro Med Tech. BSA 0,7-1,5 m2 Axial 
Excor pediatric* Berlin Heart > 2,4 kg Pusher Plate 
Table 3. Federal Drug Administration (FDA) approved, ventricular assist devices, suitable 
for children. (BSA: Body Surface Area, *Can be used for life-threathening conditions, by 
authorization.) 
3.4 Intra-aortic balloon pump (IABP) 
The main purpose of intra-aortic balloon pump is to lower the left ventricular afterload of 
patients with resistant left ventricular failure and to increase coronary perfusion. Balloon is 
positioned on the descending thoracic aorta. It is filled with helium during diastole, 
increasing the coronary blood flow. At the beginning of the systole, the balloon is deflated, 
left ventricular afterload decreases and eventually, cardiac output increases. Although, a 
sutiable balloon size is available for infants and little children, peripheral vascular 
complications related to mesenteric extremity ischemia may still occur (Akomea-Agyin et 
al., 1999). It is hard for the balloon to get in sync on children with high heart rate. There have 
been many experiences about the usage of IABP on adult patients. However, they are not 
used in routine practice for infants and little children. IABP may have a role on the 
treatment of adolescent children with left ventricular failure before placing a different 
mechanical assist device other than ECMO. 
4. Heartmate, Thoratec and the ABIOMED BVS 5000 
Several groups have successfully provided mechanical circulatory support for older children 
utilizing systems designed primarily for adult applications The use of the Heartmate VAD 
(Thoratec Corp., Pleasanton, CA) in 12 adolescent patients was described. Most of these 
patients had idiopathic dilated cardiomyopathy. The relatively older age of these patients 
(range 11–20 years) and larger size (body surface area range 1.4 – 2.2 m2) allowed the use of 
this device. As in the adult experience, the majority of children supported by the vented 
electric model were discharged home with resumption of normal activities (McBride et al., 
1999; Korfer at al., 2000). 
A number of reports exist describing experience with the Thoratec VAD (Thoratec Corp., 
Pleasanton, CA) in children. In Reinhartz’s review, 101 pediatric patients [median age 13.7 
years (range 7–17 years), median weight 54 kg (17–110 kg), median body surface area 1.5 m2 
(range 0.7–2.2 m2)] had undergone support with the Thoratec VAD worldwide with 66 % 
survival to hospital discharge (Akomea-Agyin et al., 1999). 
Ashton and et al. employed the ABIOMED BVS 5000 (ABIOMED, Inc., Danvers, MA) in four 
older children. The ABIOMED device was used to provide temporary circulatory support 
for patients with a body surface area greater than 1,2 m2 with flows greater than 2 L/ min. A 
particular limitation to more widespread pediatric application of devices designed primarily 
for adults can be attributed to low pump rates during support for all but the largest children 
limiting pump wash-out leading to increased thromboembolic risk (Ashton et al., 1995). 
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5. MEDOS HIA VAD and the Berlin Heart 
The MEDOS HIA VAD (MEDOS Medizintechnik AG, Stolberg, Germany) and the Berlin 
Heart VAD (Berlin Heart AG, Berlin, Germany) are paracorporeal pulsatile pediatric VAD 
systems. Because the systems are available in a variety of pump sizes (10–80 ml), they are 
suitable for the entire age range of pediatric patients including neonates (Shum-Tim et al., 
1997). Both are paracorporeal systems that employ pneumatically driven, flexible blood sac 
pumps, to provide pulsatile flow. Inlet and outlet valves are tri-leaflet and constructed from 
polyurethane in the smallest versions.  
Both the MEDOS and Berlin Heart systems are superior to ECMO in providing moderate to 
long-term support and preserve the options of bridging to transplantation or recovery for 
children. Also unlike ECMO, both of these systems allow extubation and ambulation during 
support with the same effects provided by similar systems designed for adults. Several 
series have been published describing use of the MEDOS system for pediatric support. 
Reinhartz reported 64 children supported with the MEDOS HIAVAD, 44 % of whom were 
supported with the smallest pump sizes with an overall survival of 38 % for patients with 
available follow-up (Reinhartz et al., 2002). The Berlin Heart VAD has fewer bleeding 
complications compared to ECMO with decreased blood product utilization during support 
(Stillert et al., 2004). A recent report showed improving results for infant support in the 
latest group of patients with survival rates now approaching those achieved in adults (Stiller 
et al., 2005). 
6. The MicroMed DeBakey VAD child (Heart Assist 5) 
The DeBakey VAD Child (MicroMed Technology, Inc. Houston, TX) became available for 
use in 2004. This pediatric device employs the same axial-flow pump used in the adult 
version with design modifications aimed at reducing the lateral space requirements for 
device implantation. These design modifications include a shortened inflow cannula with a 
more acute angle for the inflow tubing, a shortened plastic outflow graft protector and 
reduced size of the flow probe on the outflow graft. Under the current Humanitarian Device 
Exemption (HDE), the VAD Child is used to provide temporary left ventricular support as a 
bridge to cardiac transplantation for children from 5 to 16 years of age with a BSA > 0,7 m2 
and < 1,5 m2 and is designed to be fully implantable in this size range. Although the clinical 
experience is still limited, this device has been used successfully in a number of children 
since its introduction (Morales et al., 2005). 
7. Current and future developments pediatric circulatory support devices  
The clear need for better means to chronically support the circulation in infants and children 
with congenital and acquired heart disease resulting in severe heart failure has stimulated 
recent efforts to develop these much needed devices. The development of these devices is 
being funded by government agencies, industry, and institutions. The National Heart, Lung, 
and Blood Institute currently supports the development of pediatric circulatory support 
devices (Table 4). The program and the devices being developed through NHLBI support 
are described below; 
1. The PediaFlow (University of Pittsburgh; Carnegie Mellon University; Children’s 
Hospital of Pittsburgh; LaunchPoint, LLC; and World Heart Corporation) 
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2. pCAS (Ension, Inc. University of Louisville; Seare Biomatrix Systems; Fluent, Inc.) 
3. Infant- and Child-size Jarvik 2000 (Jarvik Heart, Inc.; University of Maryland Medical 
Center; Mississippi State University; Whalen Biomedical, Inc.) 
4. Penn State PVADs (Penn State University; Minnetronix, Inc.) 
5. PediPump (The Children’s Hospital at the Cleveland Clinic; The Department of 
Biomedical Engineering, The Cleveland Clinic Foundation; Foster-Miller Technologies, 
Inc.) 
7.1 Other NHLBI-supported research 
1. Pediatric pVAD (CardiacAssist)  
2. CardioFlowPQ (Ension) 
3. Miniature MagLev VAD (Levitronix) 
4. Toddler VAD (Pittsburgh/Carnegie-Mellon University) 
5. Fetal Perfusion System (Ension, Inc.)  
 
Device Research Institute Pump type 
 
PediaFlow VAD  University of Pittsburgh Axial 
PediPump  Cleveland Clinic Axial 
PCAS Ension, Inc, U Louisville Centrifugal  
Pediatric Jarvik 2000 Jarvik Heart, U Maryland Axial 
PVAD Penn State University Pneumatic pulsatile 
pusher plate 
RotaFlow  Jostra Centrifugal  
PediVAS Levitronix Centrifugal  
TinyPump Tokyo University Centrifugal  
Maglev Pump Levitronix Centrifugal (magnetic) 
TandemHeart  CardiacAssist, 
Inc.(Pittsburgh) 
Centrifugal  
Table 4. Pediatric VADs in development under the NHLBI pediatric circulatory support 
program (current and future) 
8. Patient selection criteria 
With the development of new mechanical devices and the increase in ECMO usage, criteria 
for device usage have improved continuously. Therefore, patient selection cirtieria has 
become far more important. 
• Progression of the disease in spite of high-dose traditional treatment. 
• If the purpose is not bridging to transplantation with mechanical support, heart and/or 
pathophysiology is potentially reversible. 
• The hemodynamics is important. Corrective surgery must be conducted and the 
residual lesion must be defined. Otherwise the presence of an undefined defect may 
risk the possibility of minimal recuperation and hemodynamic recovery. The detailed 
postoperative evaluation, ecocardiography, heart catheterization, computerized 
tomography or magnetic resonance are all of vital importance for the patient. 
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• The patient must not face with other complications in the intensive care unit. For 
instance, if there is a cerebral hemorrhage where anticoagulation is contraindicated or if 
there is a neurologic damage due to hypoxic ischemic encephalopathy, the intensive 
care support must continue. With a practical point of view, it is not always possible to 
evaluate the neurological functions of the patient. 
In these circumstances, if there is any skepticism about the benefits of the support for the 
patient, the mechanical support must come to an end, right after neurological function tests. 
This decision depends on the expectations of the patient’s family. 
9. The purpose of using mechanical support devices 
The main purpose is to provide with suitable physiological environement and time for 
myocardial recuperation by transferring oxygen to the vital organs, when traditional drug 
treatment fails. Therefore, stress and myocardial oxygen consumption across the ventricular 
wall will decrease and adequate coronary perfusion will be provided. 
The aim of mechanical cardiac support is to help recover from myocardial failure with 
effects on heart transplantation and even bridging. Ventricular assist devices and all other 
new designs are used for pediatric population with the aim of destination therapy. 
10. Timing and indications for mechanical support 
There are 3 groups for pediatric mechanical cardiac indications: 
1. Patients who develop postcardiotomy syndrome 
2. Patients with circulatory failure due to myocarditis and cardiomyopathy  
3. Patients with heart failure that develops secondary to sepsis pressure (In this section, 
this will not be discussed with details, but these mechanical support devices have 50-60 
% success rate.) (Goldman et al., 1997). 
10.1 Postcardiotomy circulatory failure 
Mechanical assist devices are sometimes required for pediatric patients with structural heart 
disease following a heart surgery. Imflammatory response to cardiopulmonary bypass, 
direct myocardial damage due to surgery, myocardial ischemia due to aortic cross clemp 
time and reperfusion damage and eventually myocardial dysfunction caused by myocardial 
exhaustion with postcardiotomy syndrome develop. The repair of anatomic residual lesions 
that causes circulatory failure is of vital importance. On the other hand, mechanical support 
indication is low for postcardiotomy patients with malign arrhythmia and resistant 
pulmonary hypertension. 
For the selection of the correct time for starting mechanical support, the risk of organ failure, 
which depends on the length of time that the patient is going through an invasive treatment 
like ECMO, must be taken into account. However, ECMO’s oxygenation index does not 
have effective results for preventing a severe disease. With this sensitivity, there are some 
approaches for the timing of mechanical support in different centers. In spite of suitable 
vasoactive drug treatment, so many centers activate the postoperative mechanical support 
with the deterioration of clinical symptoms of oxygen transfer (increase of lactate, decrease 
of mixed venous oxygen saturation, peripheral cooling, oliguria and other syptoms of end-
organ ischemia). In order to avoid organ damage during low cardiac output period, some 
centers start mechanical support without waiting for the response of drug treatment, due to 
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their concern for myocardial damage that is related to usage of high doses of epinephrine 
(Reinhartz et al., 2001). Another point of view is that, in spite of the increase of inotropic 
support (approx. 0,3 microgram/kg/min dose of epinephrine), the mechanical support 
must be activated due to deteriorating symptoms of low cardiac support. Some centers 
recommend the usage of VAD in semi effective conditions for postcardiotomy patients who 
develop severe left ventricular failure after ALCAPA (anomalous left coronary artery from 
the pulmonary artery) procedure and arterial switch operation (survival rate is 90 %) (Del 
Nido et al., 1999; Kang et al., 2004). 
Some other centers support the usage of VAD, after Norwood Stage 1 operation. Thereby, 
within 48 hours of the surgery, the patient is protected from the risk of possible neurological 
disease in later stages by maintaining the brain oxygenation. Another center did not defend 
mechanical support after Norwood stage 1 operation, in spite of 80 % survival rate that was 
reported in the very early reviews. While the short term benefit of this support kept out  of 
view, neurological disease must be monitored for long term (Chaturvedi et al., 2004). In 
another report, while distinguishing a patient with a failure from cardiopulmonary bypass, 
morbidity and mortality increase, like hemorrhage, was detected (Duncan et al., 1999). 
In univentricular and biventricular anatomy, mechanical support indication is related with 
reversibility potential of myocardial dysfunction, rather than cardiac anatomy as a result. 
Therefore, patients with single ventricular function may undergo operation, surgical 
treatment of complex heart lesions would become possible and reversibility potential is 
maintained with mechanical support indication. 
10.2 Circulatory failure due to myocarditis and cardiomyopathy  
In popular belief, while heart failure due to cardiymyopathy is a long term disease, 
myocardial failure on pediatric patients diagnosed with myocarditis, is a fulminant disease 
that explodes suddenly. Although there are major differences in these two diseases, it is 
nearly impossible to specify them. It is not always possible to get a diagnosis with 
myocardial biopsy. It is possible to disconnect the patients with long term cardiomyopathy 
who require transplantation with signs of acute deterioration, from mechanical support. The 
importance of the mechanical support and the patients with myocarditis is not rare among 
some surgeons. Therefore, the mechanical support for these two groups of patients with 
acute heart failure is suitable. The main purpose of the support is bridging treatment. 
The most suitable period for the timing of the mechanical support for these patients is the 
same with postcardiotomy patients. Development of arryhtmia, intolerance to enteral nutrition 
and oliguric renal failure are usually bad news. By taking precautions, the wellbeing of the 
patient must be assured in semi-elective circumstances. 
At the end of the first week, if the ventricular function deteriorates, the main purpose must 
be bridging to transplantation. In this case, long term (monthly) support machines must be 
considered. 
11. Emergency ECMO or extracorporeal cardiopulmonary resuscitation 
(ECPR) 
For patients with, severe problems after a long term cardiac arrest, extracorporeal 
cardiopulmonary resuscitation (ECPR) is highly recommended for high risk of neurological 
damage. The succesful results of ECMO placement during cardiac arrest have been 
reviewed many times recently and have a survival rate of 40 % (Duncan et al., 1998; Morris 
et al., 2004). The patients who have suffered due to cardiac arrest longer than 60 minutes, 
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continue their neurological life. The results of neurological studies for these patients are 
important, as these studies prove that they deserve a life in future. The lifesaving effect of 
ECPR program is that, the surgeon and the surgical nurse are required to have sufficient 
knowledge, education and cannulation skills for ECMO circulation. So, many centers must 
have specialists with ECMO experience in their intensive care unit, as an alternative 
approach. The latest studies show that if crystalloid solution applied with ECMO properly, 
circulatory support for more than 2 weeks can be maintained (Karimova et al., 2005). ECPR 
can be improved by this method. It can be stressful to opt for ECMO as a last option for 
patients with cardiac arrest. With strategic assessments performed under all circumstances, 
ECMO can be preferred as an early response. 
12. Practical point of view for mechanical support  
12.1 Cannulation 
Veno-arterial ECMO for pediatric patients is performed by inserting cannula into the carotid 
artery (right carotid artery and right internal jugular vein and femoral vein cannulation) or 
by surgical procedure of median sternotomy. ECMO cannulation technique for neonates 
which was introduced by Karl in 1990, allows the preservation of carotid and jugular vessels 
(Karl et al., 1990). Silastic vessel-loop technique provides adequate hemostasis during 
ECMO cannulation and allows the reconstruction of the vessels during decannulation. 
In patients in whom separation from cardiopulmonary bypass is difficult, further support 
with ECMO may be useful and aorta and right atrium must be prepped for cannulation. Left 
atrial vent is placed in some patients where necessary. Postcardiotomoy patients who are 
undergoing or about to undergo cardiac arrest must be urgently provided with cannulation. 
If there is enough time and no contraindications, carotid cannulation must be performed. In 
this way, the risk of infection and bleeding will be minimized. 
In an aortic valve failure and impaired left ventricular function, it is important that the left 
heart must be decompressed. In these circumstances, the pressure of left atrium increases 
(above 30 mmHg) and lung congestion develops. Left ventricular diastol pressure increases 
the ventricular wall stress and coronary perfusion deteriorates. Decompression of the left 
ventricle can be achieved in catheterization laboratory by atrial connection and by direct 
placement of the left ventricle. 
12.2 Bleeding control 
Severe bleeding is one of the most important complications of postoperative cardiac ECMO. 
If the bleeding starts unexpectedly, severe blood transfusion will be required. With the 
deterioration of the coagulopathy, bleeding increases more.  
The following are necessary for the control of postcardiotomy bleeding; 
• Improving coagulopathy rapidly (giving thrombocyte transfusion until thrombocytes > 
100.000 and cryoprecipitate until fibrinogen > 2 gl/l) 
• Keeping activated clotting time (ACT) level between 160-180 seconds (In early stages, it 
is recommended that activated partial thromboplastin time (aPTT) level must be 
between 60-80 seconds. The effect of heparin and coagulation ii determined by heparin 
level, activated factor X and thromboelestogram) 
• Application of antifibrinolytic agents (Aprotinin) 
• If bleeding continues inspite of improvement of coagulopathy (>10 ml/kg/sec), the 
thorax might be opened again. 
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• Opting for carotid cannulation at the neck 
• Using the cell-saver device. 
• If the bleeding still continues, heparin needs to be cut off within 4-6 hour period until 
bleeding is stopped (A back-up ECMO circuit must be available at all times). 
• In recent years, the usage of recombinant factor VII has been put forward for 
postcardiotomy patients with resistant bleeding. But routine usage of this treatment is 
yet to be recommended until the effects are tested by random studies (Pychynska-
Pokorska et al., 2004). 
13. Mechanical support complications 
There are 4 important complications about the usage of cardiac ECMO by ELSO 
(Extracorporeal Life Support Organization) (Bartlett et al., 1977): 
• 30 % bleeding 
• Risk of infection (about 30 %) 
• Cerebral hemorrhage and infarct (6 % in little children and 12 % in neonates) 
• Pump, oxygenation or circulatory failure (10 %) 
The most important complications of paracorporeal devices are cerebral symptoms 
(hemorrhage and thromboembolia) infection and must be diagnosed in the early stages.  
14. Efficiency of ECMO 
For the assessment, end organ perfusion markers must be checked. Acid-base equilibrium, 
lactate and mixed venous oxygen saturation, urine output are also put into assessment. The 
most suitable ECMO flow that enables ventricular improvement is usually 200 ml/kg/sec. 
The minimum flow that decompresses the ventricle and provides the oxygen transfer may 
also be favoured. 
In oxygen deficiency, hematocrit level must be around 40 % and blood must be separated 
from oxygenator and adequate oxygen saturation must be maintained. The blood flow can 
be measured by ultrasonic assessment of the distal section that contains the real blood flow 
that enables the re-circulation of the patient and which is a bridge to arterial ECMO line. 
When the real blood flow of the device cannot be measured, bridge to circulation must be 
clamped and roller pump must be controlled. If symptoms of circulatory failure still occur in 
spite of these manouvers, there must be an increase in the demand of pump flow for the 
metabolic needs of the patient. Even at the high flow rate (>200 ml/kg/sec), end-organ 
circulation may not be maintained. In order to decrease the metabolic requirements of the 
patient, 34 oC perfusion might be considered. Vasodilatory drugs can be used to control 
hypertension while afterload is reduced within necessary intervals. Centrifugal pumps are 
very important in terms of reducing the afterload and maintaining high volume (Right atrial 
pressure > 5 mmHg). 
15. The use of ECMO for patients with systemic-pulmonary shunt 
On patients with Blalock-Taussig shunt (BT shunt) who has undergone Norwood Stage I 
procedure, the use of VADs is favoured. It can be applied on circumstances where there is 
no lung problem (Ungerleider et al., 2004). It has been claimed that VAD flow must be at 
high volume (around 200 ml/kg/minute) in order to provide adequate systemic perfusion 
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and compensate the patients with shunt. On these patients, if ECMO is applied, shunt 
thrombosis or pulmonary infarction may occur (Jaggers et al., 2000). 
The patients who are going through Norwood procedure Stage I with Sano modification, are 
in need of mechanical support. Here, they require ECMO, rather than VAD. Because, in this 
physiology, adequate blood flow may not be available in the lungs. In this case, an oxygenator 
is a must. 
16. The follow-up of the patients with mechanical support 
There are various physiological approaches; enteral nutrition, a little sedation, the care of 
the patient’s relatives are important. ECMO ventilation must be adjusted according to the 
resting mode.The tidal volume must be 5-10 ml/kg (highest inspiration pressure to be 25 
cmH2O), PEEP to be 7-10 cmH2O and ventilation rate to be 15-20/min. In order to avoid 
pulmonary desaturation, FiO2 ventilator must be adjusted to 40 %. Unlike ECMO, patients 
with VAD, full ventilation is compulsory. Antibiotics are not routinely necessary for patients 
with ECMO. However, daily blood culture monitoring and starting the treatment with the 
presence of an infection are acceptable approaches. 
17. Separation from ECMO (Weaning) 
One of the difficulties of ECMO is not being able to determine the clues of ventricular 
improvement that allows the separation from cardiac mechanical support unit. Practically, 
the paitent is laid to rest for 48-72 hours, with ECMO support. Later, inotropic perfusiom 
application (adrenaline or dopamine, combined with milrinone), left atrial vent is clamped 
and device flow speed is is decreased gradually within two hours until the lowest safe flow 
is maintained (100-200 ml/minute). However, due to risk of coagulation ECMO flow must 
not be reduced below this level. If the flow is reduced successfully without risking the 
hemodynamics, the patient is ready to separate from the ECMO. In this 2-3 hour period, the 
patient tries to separate from ECMO and then the patient is decannulated. Ecocardiography 
is used for the evaluation of the ventricular functions. Besides, complications such as, 
undiagnosed lesions, pulmonary hypertension, akinesia, dyskinesia, pericardial effusion 
must be re-assessed. If a failure occurs during the separation from ECMO, this is due to 
inefficiency of the oxygen transfer to the tissues and hemodynamic disturbance. Therefore 
ECMO support must be re-started immediately and must wait for another 48 hours. This 
period is best for ventricular recovery and improvement. 
18. When to end the mechanical support? 
In mechanical support, healing process depends on available pathology. In postcardiotomy 
patients, myocardial stunning is the basis (Aharon et al., 2001). According to Duncan’s 
suggestion, if signs of ventricular improvement do not occur in this period, the patients 
must be put on the early transplant list. The timing depends on the organ availability. The 
separation from mechanical support of the patient who will not undergo transplantation 
after showing effective signs of cardiac recovery is very important. Survival time with 
ECMO support is maximum 10 days (Reinhartz et al., 2001; Chaturvedi et al., 2004). In spite 
of surviving patients who had mechanical support for more than 250 hours, recovery 
expectancy is highly low for patients who remained under ECMO support for more than 10 
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days (Morris et al., 2004). After 2 weeks of mechanical support on a patient who is not a 
transplant candidate, if there are no signs of improvement of ejection fraction, mechanical 
support must be suspended, according to the practical approach. 
One of the most common problems faced with during cardiac ECMO is inefficiency of 
determining the signs of ventricular recovery. On patients that are separated from 
mechanical support, traditional echocardiography and oxygen transfer markers are used. In 
recent years, myocardial tissue Doppler, with its precision to indicate ventricular 
improvement, is used in evaluating myocardial function (Cheung & Redington, 2004). 
Patients with myocarditis can be separated after 2 weeks of mechanical support. These 
patients will immediately show signs of recovery. If separation from the support (weaning) 
is inefficient and if the patient is a transplant candidate, the mechanical support must 
resume as a treatment for bridging to transplantation (Duncan et al., 2001). Besides, there 
can be limiting factors such as availability of the appropriate mechanical assist device to 
match the heart of the donor.  
In some patients with cardiomyopathy, after 2-3 week period, adequate ventricular 
improvement of ECMO weaning had been detected. These patients are put into transplant 
list and a very close follow-up is done (McMahon et al., 2003). 
Although there is an increase in the number of pediatric ECMO applications, it is 
disappointing that the survival rate still remains at 40 % for postcardiotomy patients who 
have undergone mechanical support (ECLS Registry, 2005). When we take a look at the 
survival rates, we can see some positive changes, if the support is started in semi-elective 
circumstances during cardiac arrest. The changes are independent from the usage of 
mechanical support (Del Nido et al., 1999; Morris et al., 2004). After weaning from assist 
device, the improvement of low cardiac output that is associated with patients with multi 
organ failure, neurological complications ensue before ECMO procedure starts (Hintz et al., 
2005). 
In spite of optimal medical treatment, left ventricular assist devices have not been successful 
on patients with multi-organ failure. Therefore, with the semi-elective implantation of VAD 
applications, better results are expected for bridging to transplantation than that of 
resuscitative implantation. Patients that are expected to undergo left VAD implantation, 
some cardiac and non-cardiac factors must be analyzed thoroughly. Among these, right 
heart failure is the most important cause of perioperative mortality. During chronic heart 
failure, pulmonary vascular resistance (PVR) increases. It usually comes back to normal 
after transplantation or left ventricular assist device implantation. However, on right 
ventricular failure that develops severe damage due to left ventricular failure, only left VAD 
implantation requires biventricular support (Kucukaksu et al., 2002). 
Left VAD implantation has both desired and unwelcome effects on right ventricle. The 
most important effect of left VAD on right ventricle is the decrease of afterload and thus 
the increase of right ventricular output. However, on 20-50 % of patients who are 
implanted with left VAD, right ventricular dysfunction is developed. Right VAD must be 
implanted on patients who have developed right ventricular dysfunction. However, if it is 
spotted early and inotropic agents, pulmonary vasodilators and phosphodiesterase 
inhibitors are infused, there might not be a need for right VAD. Therefore the early selection 
of the patients is clinically important. The patients who require left VAD, while waiting for 
heart transplant, must be assessed carefully in terms of right ventricular failure (Tarcan et 
al., 2004). 
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19. Costs related to ventricular assist device for pediatric use 
Historically children with severe heart failure had a significant risk of death while awaiting 
transplantation. However, the overall survival to transplantation with this strategy is less 
than 50 %, and the need for ECMO support before transplantation is associated with poorer 
posttransplant survival (Boucek et al., 2007). The use of VAD therapy to support children 
with advanced heart failure has increased in the last several years. This increase is related to 
several factors, including availability of VAD devices for small children and more favorable 
outcomes in published series. This present study supports the notion that VAD support 
allows a significant number of children to survive to either heart transplantation or device 
explantation. The costs of VAD support are considerable greater than $ 500,000 per initial 
hospitalization and the calculated incremental cost-effectiveness ratio is high even when 
compared against most other complex pediatric medical interventions. The cost of VAD 
support in adults has been intensely studied. Investigators have examined both VAD as a 
bridge to transplantation and VAD as destination. Analyzing VAD as a destination therapy 
appears somewhat more favorable (Carrier, 2005). 
The study assumes that the quality of life after transplant for children who received VAD 
support is similar to that of other transplant recipients. However, the occurrence of acute 
neurologic events such as stroke for children supported with VAD may impact later quality 
of life. In adults stroke occurs in 25% of patients supported for 6 months or longer (Tsukui et 
al., 2007). Limited data from children would suggest that the risk of stroke is the same if not 
higher than in adults (Malaisrie et al., 2008). Stroke appears to impair children’s social 
ability along with their neurologic function (Lo et al., 2008). The use of pretransplant VAD 
has been identified with poorer neurologic function in adults after transplantation (Zierer et 
al., 2007). In addition, it is assumed that children who undergo VAD implantation have 
equivalent posttransplant survival to those not receiving VAD support.  
Follow-up medical costs are substantial, adding to the overall costs. The costliness of VAD 
support has been a concern for health-policy officials, engendering much debate. The 
Canadian government initially limited the use of VAD support, concerned that the cost-
effectiveness was unfavorable (McGregor et al., 2000). The costs of postoperative care will be 
difficult to modify. One strategy might be to discharge a significant number of children from 
the hospital so that they might be able to wait at home for an available organ. Certainly, 
adult centers now have a wealth of experience with home VAD management (Oosterom et 
al., 2007). Previous investigators have shown that home inotropic medication can be 
administered safely and inexpensively to children awaiting transplantation (Berg et al., 2007). 
A shorter waiting time would also reduce overall costs. Lastly, the neurodevelopmental 
outcome of survivors is largely unknown. Children with VAD support before transplantation 
may have a significantly poorer quality of life than other pediatric transplant recipients. In 
summary, using VAD support for children with advanced heart failure permits the majority 
of children to be bridged to heart transplantation. The costs related to this strategy are 
relatively high and by some standards exceed the threshold for acceptable cost effectiveness. 
In light of the rapid pace of evolution in VAD technology one hopes that novel approaches 
can both improve the outcomes and lower the costs associated with VAD support in children. 
20. Conclusion  
As a summary, the results of patients with myocarditis or cardiomyopathy are highly 
positive. On patients with myocarditis, if the assist device is used as a treatment for bridging 
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to transplantation, the survival rate is 70 % (Acker, 2001). On pediatric population, 
treatment for mechanical bridging to transplantation has highly successful results. While 
survival rate with transplantation is 70-80 %, successful discharge from the hospital is 
around 70 % (Goldman et al., 2003; Levi et al., 2002). One of the difficulties that relates to the 
pediatric population for mechanical support team is that, there are more than one 
ventricular assist devices in use for neonates and children for long term support. The studies 
of these pediatric cardiac support devices (PediaFlow VDC, PediPump, PCAS, Pediyatrik 
Jarvik 2000, TinyPump, TandemHeart, RotaFlow) still continue for future use (Table 4). 
Ideally, these devices have to be implanted on the patient easily. There is a requirement for 
advanced technology that allows biologically compatible tube systems without the need of 
systemic anticoagulation. In addition to this, there must be better techniques that evaluate 
the ventricular function. This will be a guide to the surgeon in decision making about both 
starting the mechanical support and weaning from it. CE marking shows that the product 
has met European standards regarding consumer safety, health or environmental 
requirements and is an abbreviation for Conformité Européenne (European Conformity). 
There is not price difference of the VAD in Europe and USA. The price of short term devices 
is between 8-12.000 €, paracorporeal systems 25-50.00 € and axial flow systems (double 
sided) are about 110.000 €. In recent years, the studies for the manufacture of cardiac 
support devices in all shapes and sizes still continue to rise. All kind of improvement on this 
subject is a source of hope for the humankind. The objective for future is to provide 
permanent solutions. 
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